| Drug Design and Development Section
|
 |
Nigel H. Greig, Ph.D., Chief
Senior Investigator |
| Overview: The Drug Design and Development Section (DDDS) is designed to identify drugs that improve brain function and/or forestall the neurodegenerative process in age-related neurodegenerative disorders. Data arising from studies on neurodegenerative and neuroprotective signaling pathways are used to identify potential drug targets. Candidate drugs are first screened for efficacy in cell culture or animal models, and the most effective compounds are moved through preclinical studies to clinical trials. Several drugs that enhance cognitive function are currently in clinical trials, and novel neuroprotective compounds are at various preclinical stages of development. |
 |
| Left to right: Ryan Short, David Tweedie, Yazhou Li, Harold Holloway, Nigel Greig, Qian-Sheng Yu, Weiming Luo |
| |
